Bernzott Capital Advisors Invests $4.49 Million in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Bernzott Capital Advisors bought a new position in Halozyme Therapeutics, Inc. (NASDAQ:HALO) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 93,985 shares of the biopharmaceutical company’s stock, valued at approximately $4,493,000. Halozyme Therapeutics accounts for 2.2% of Bernzott Capital Advisors’ holdings, making the stock its 28th largest holding. Bernzott Capital Advisors owned approximately 0.07% of Halozyme Therapeutics as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently modified their holdings of the stock. Verdence Capital Advisors LLC boosted its position in shares of Halozyme Therapeutics by 1.9% in the third quarter. Verdence Capital Advisors LLC now owns 13,232 shares of the biopharmaceutical company’s stock worth $757,000 after buying an additional 252 shares during the period. GAMMA Investing LLC boosted its position in shares of Halozyme Therapeutics by 67.7% in the third quarter. GAMMA Investing LLC now owns 867 shares of the biopharmaceutical company’s stock worth $50,000 after buying an additional 350 shares during the period. Juncture Wealth Strategies LLC boosted its position in shares of Halozyme Therapeutics by 3.6% in the third quarter. Juncture Wealth Strategies LLC now owns 12,058 shares of the biopharmaceutical company’s stock worth $690,000 after buying an additional 415 shares during the period. Diversify Advisory Services LLC boosted its position in shares of Halozyme Therapeutics by 8.5% in the third quarter. Diversify Advisory Services LLC now owns 5,331 shares of the biopharmaceutical company’s stock worth $305,000 after buying an additional 418 shares during the period. Finally, Sheaff Brock Investment Advisors LLC boosted its position in shares of Halozyme Therapeutics by 7.7% in the third quarter. Sheaff Brock Investment Advisors LLC now owns 7,118 shares of the biopharmaceutical company’s stock worth $407,000 after buying an additional 507 shares during the period. Hedge funds and other institutional investors own 97.79% of the company’s stock.

Halozyme Therapeutics Trading Up 1.6 %

Shares of NASDAQ HALO opened at $55.37 on Friday. The stock’s 50 day moving average price is $49.75 and its two-hundred day moving average price is $54.07. Halozyme Therapeutics, Inc. has a 52-week low of $33.15 and a 52-week high of $65.53. The stock has a market capitalization of $7.04 billion, a P/E ratio of 18.33, a PEG ratio of 0.40 and a beta of 1.24. The company has a quick ratio of 9.15, a current ratio of 10.36 and a debt-to-equity ratio of 3.32.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on HALO. Wells Fargo & Company decreased their target price on Halozyme Therapeutics from $62.00 to $57.00 and set an “equal weight” rating for the company in a research report on Monday. Piper Sandler boosted their price target on Halozyme Therapeutics from $52.00 to $53.00 and gave the stock a “neutral” rating in a research note on Friday, January 10th. Cowen reiterated a “buy” rating on shares of Halozyme Therapeutics in a research note on Friday, October 18th. HC Wainwright boosted their price target on Halozyme Therapeutics from $68.00 to $70.00 and gave the stock a “buy” rating in a research note on Friday, January 10th. Finally, JPMorgan Chase & Co. cut Halozyme Therapeutics from an “overweight” rating to a “neutral” rating and boosted their price target for the stock from $52.00 to $57.00 in a research note on Thursday, September 19th. Four analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. According to data from MarketBeat.com, Halozyme Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $60.89.

Insider Buying and Selling at Halozyme Therapeutics

In other news, Director Jeffrey William Henderson sold 10,000 shares of the stock in a transaction that occurred on Monday, January 6th. The stock was sold at an average price of $50.01, for a total transaction of $500,100.00. Following the sale, the director now directly owns 43,611 shares in the company, valued at approximately $2,180,986.11. This represents a 18.65 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 2.40% of the stock is currently owned by insiders.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.